Assessment of APAF1 in different human leukemia relative to the 96 biologic groups Human Expression Map
| Group | APAF1 | |||||
|---|---|---|---|---|---|---|
| 204859_s_at | 211553_s_at | 211554 _s_at | ||||
| Expression Change | P Value | Expression Change | P Value | Expression Change | P Value | |
| Acute lymphoblastic leukemia (n = 95) | + | <1 × 10−10 | + | <1 × 10−10 | + | 5.49 × 10−9 |
| Acute myeloid leukemia (n = 295) | + | <1 × 10−10 | + | <1 × 10−10 | + | <1 × 10−10 |
| Acute promyelocytic leukemia (n = 18) | − | 0.018 | + | 1.27 × 10−6 | +/− | 0.19 |
| Chronic myeloid leukemia (n = 44) | + | <1 × 10−10 | + | <1 × 10−10 | + | <1 × 10−10 |
| Myelogenous leukemia (n = 37) | +/− | 0.269 | + | 6.69 × 10−4 | +/− | 0.685 |
| Precursor T-lymphoblastic leukemia (n = 59) | + | 0.003 | − | <1 × 10−10 | + | 0.003 |
Assessment of APAF1 expression in the Human Gene Expression Map (Lukk et al., 2010). The database encompasses 5372 samples hybridized to the Affymetrix HG-U133A platform and enables the comparison of the expression levels relative to 96 biologic groups. Here, the expression of APAF1 in subtypes of leukemia was determined relative to the 96 groups (Kwiecinska et al., 2011). Direction of change and P values, respectively, are indicated. Significant increased expression is indicated by plus (+), significant decreased expression indicated by minus (−) and non-differentially expressed is indicated by +/−. A P value of 0.05 was considered significant.